APO Research
Talk to an analyst

APO RESEARCH · REPORT

Breakthrough Therapies

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Breakthrough Therapies Market Analysis and Forecast 2026-2032

15 April 2026202 pages

Choose your research edition.

Industry ResearchBreakthrough Therapies Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Breakthrough Therapies Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Breakthrough Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Breakthrough Therapies Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Breakthrough Therapies Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Breakthrough Therapies market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Breakthrough Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Breakthrough Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Breakthrough Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Breakthrough Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Breakthrough Therapies include F. Hoffmann-La Roche, Merck & Co., Bristol-Myers Squibb, Novartis, AstraZeneca, Johnson & Johnson, Pfizer and AbbVie, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Breakthrough Therapies, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Breakthrough Therapies, also provides the revenue of main regions and countries. Of the upcoming market potential for Breakthrough Therapies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Breakthrough Therapies revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Breakthrough Therapies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Breakthrough Therapies revenue, projected growth trends, production technology, application and end-user industry.

Breakthrough Therapies Segment by Company

F. Hoffmann-La Roche

Merck & Co.

Bristol-Myers Squibb

Novartis

AstraZeneca

Johnson & Johnson

Pfizer

AbbVie

Breakthrough Therapies Segment by Type

Targeted Therapy

Immunotherapy

Gene Therapy

Cell Therapy

Other

Breakthrough Therapies Segment by Application

Cardiovascular

Central Nervous System and Neurology

Rare Diseases

Oncology

Others

Breakthrough Therapies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Breakthrough Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Breakthrough Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Breakthrough Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Breakthrough Therapies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Breakthrough Therapies company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Breakthrough Therapies revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Breakthrough Therapies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Targeted Therapy Major Player Table 3. Immunotherapy Major Player Table 4. Gene Therapy Major Player Table 5. Cell Therapy Major Player Table 6. Other Major Player Table 7. Global Breakthrough Therapies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Cardiovascular Major Player Table 9. Central Nervous System and Neurology Major Player Table 10. Rare Diseases Major Player Table 11. Oncology Major Player Table 12. Others Major Player Table 13. Breakthrough Therapies Industry Trends Table 14. Breakthrough Therapies Industry Drivers Table 15. Breakthrough Therapies Industry Opportunities and Challenges Table 16. Breakthrough Therapies Industry Restraints Table 17. Global Breakthrough Therapies Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Breakthrough Therapies Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Breakthrough Therapies Market Share by Region (2021-2026) Table 20. Global Breakthrough Therapies Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Breakthrough Therapies Market Share by Region (2027-2032) Table 22. Global Breakthrough Therapies Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Breakthrough Therapies Revenue Market Share by Players (2021-2026) Table 24. Global Breakthrough Therapies Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Breakthrough Therapies Key Players Headquarters & Area Served Table 26. Global Breakthrough Therapies Players, Product Type & Application Table 27. Global Breakthrough Therapies Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Breakthrough Therapies by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Breakthrough Therapies Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Breakthrough Therapies Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Breakthrough Therapies Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Breakthrough Therapies Revenue Market Share by Type (2021-2026) Table 34. Global Breakthrough Therapies Revenue Market Share by Type (2027-2032) Table 35. Global Breakthrough Therapies Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Breakthrough Therapies Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Breakthrough Therapies Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Breakthrough Therapies Revenue Market Share by Application (2021-2026) Table 39. Global Breakthrough Therapies Revenue Market Share by Application (2027-2032) Table 40. F. Hoffmann-La Roche Company Information Table 41. F. Hoffmann-La Roche Business Overview Table 42. F. Hoffmann-La Roche Breakthrough Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. F. Hoffmann-La Roche Breakthrough Therapies Product Portfolio Table 44. F. Hoffmann-La Roche Recent Development Table 45. Merck & Co. Company Information Table 46. Merck & Co. Business Overview Table 47. Merck & Co. Breakthrough Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Merck & Co. Breakthrough Therapies Product Portfolio Table 49. Merck & Co. Recent Development Table 50. Bristol-Myers Squibb Company Information Table 51. Bristol-Myers Squibb Business Overview Table 52. Bristol-Myers Squibb Breakthrough Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Bristol-Myers Squibb Breakthrough Therapies Product Portfolio Table 54. Bristol-Myers Squibb Recent Development Table 55. Novartis Company Information Table 56. Novartis Business Overview Table 57. Novartis Breakthrough Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Novartis Breakthrough Therapies Product Portfolio Table 59. Novartis Recent Development Table 60. AstraZeneca Company Information Table 61. AstraZeneca Business Overview Table 62. AstraZeneca Breakthrough Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. AstraZeneca Breakthrough Therapies Product Portfolio Table 64. AstraZeneca Recent Development Table 65. Johnson & Johnson Company Information Table 66. Johnson & Johnson Business Overview Table 67. Johnson & Johnson Breakthrough Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Johnson & Johnson Breakthrough Therapies Product Portfolio Table 69. Johnson & Johnson Recent Development Table 70. Pfizer Company Information Table 71. Pfizer Business Overview Table 72. Pfizer Breakthrough Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Pfizer Breakthrough Therapies Product Portfolio Table 74. Pfizer Recent Development Table 75. AbbVie Company Information Table 76. AbbVie Business Overview Table 77. AbbVie Breakthrough Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. AbbVie Breakthrough Therapies Product Portfolio Table 79. AbbVie Recent Development Table 80. North America Breakthrough Therapies Revenue by Type (2021-2026) & (US$ Million) Table 81. North America Breakthrough Therapies Revenue by Type (2027-2032) & (US$ Million) Table 82. North America Breakthrough Therapies Revenue by Application (2021-2026) & (US$ Million) Table 83. North America Breakthrough Therapies Revenue by Application (2027-2032) & (US$ Million) Table 84. North America Breakthrough Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. North America Breakthrough Therapies Revenue by Country (2021-2026) & (US$ Million) Table 86. North America Breakthrough Therapies Revenue by Country (US$ Million) & (2027-2032) Table 87. Europe Breakthrough Therapies Revenue by Type (2021-2026) & (US$ Million) Table 88. Europe Breakthrough Therapies Revenue by Type (2027-2032) & (US$ Million) Table 89. Europe Breakthrough Therapies Revenue by Application (2021-2026) & (US$ Million) Table 90. Europe Breakthrough Therapies Revenue by Application (2027-2032) & (US$ Million) Table 91. Europe Breakthrough Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. Europe Breakthrough Therapies Revenue by Country (2021-2026) & (US$ Million) Table 93. Europe Breakthrough Therapies Revenue by Country (US$ Million) & (2027-2032) Table 94. China Breakthrough Therapies Revenue by Type (2021-2026) & (US$ Million) Table 95. China Breakthrough Therapies Revenue by Type (2027-2032) & (US$ Million) Table 96. China Breakthrough Therapies Revenue by Application (2021-2026) & (US$ Million) Table 97. China Breakthrough Therapies Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia Breakthrough Therapies Revenue by Type (2021-2026) & (US$ Million) Table 99. Asia Breakthrough Therapies Revenue by Type (2027-2032) & (US$ Million) Table 100. Asia Breakthrough Therapies Revenue by Application (2021-2026) & (US$ Million) Table 101. Asia Breakthrough Therapies Revenue by Application (2027-2032) & (US$ Million) Table 102. Asia Breakthrough Therapies Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Asia Breakthrough Therapies Revenue by Region (US$ Million) & (2021-2026) Table 104. Asia Breakthrough Therapies Revenue by Region (US$ Million) & (2027-2032) Table 105. SAMEA Breakthrough Therapies Revenue by Type (2021-2026) & (US$ Million) Table 106. SAMEA Breakthrough Therapies Revenue by Type (2027-2032) & (US$ Million) Table 107. SAMEA Breakthrough Therapies Revenue by Application (2021-2026) & (US$ Million) Table 108. SAMEA Breakthrough Therapies Revenue by Application (2027-2032) & (US$ Million) Table 109. SAMEA Breakthrough Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. SAMEA Breakthrough Therapies Revenue by Country (2021-2026) & (US$ Million) Table 111. SAMEA Breakthrough Therapies Revenue by Country (US$ Million) & (2027-2032) Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Breakthrough Therapies Image Figure 2. Global Breakthrough Therapies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Breakthrough Therapies Market Size Share 2021 VS 2025 VS 2032 Figure 4. Targeted Therapy Image Figure 5. Immunotherapy Image Figure 6. Gene Therapy Image Figure 7. Cell Therapy Image Figure 8. Other Image Figure 9. Global Breakthrough Therapies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Breakthrough Therapies Market Size Share 2021 VS 2025 VS 2032 Figure 11. Cardiovascular Image Figure 12. Central Nervous System and Neurology Image Figure 13. Rare Diseases Image Figure 14. Oncology Image Figure 15. Others Image Figure 16. Global Breakthrough Therapies Market Size (US$ Million) & (2021-2032) Figure 17. Global Breakthrough Therapies Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Breakthrough Therapies Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Breakthrough Therapies Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Breakthrough Therapies Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Breakthrough Therapies Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Breakthrough Therapies Revenue Market Share by Type (2021-2032) Figure 24. Global Breakthrough Therapies Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Breakthrough Therapies Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Breakthrough Therapies Revenue Market Share by Application (2021-2032) Figure 27. North America Breakthrough Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Breakthrough Therapies Revenue Share by Type (2021-2032) Figure 29. North America Breakthrough Therapies Revenue Share by Application (2021-2032) Figure 30. North America Breakthrough Therapies Revenue Share by Country (2021-2032) Figure 31. United States Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Breakthrough Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Breakthrough Therapies Revenue Share by Type (2021-2032) Figure 36. Europe Breakthrough Therapies Revenue Share by Application (2021-2032) Figure 37. Europe Breakthrough Therapies Revenue Share by Country (2021-2032) Figure 38. Germany Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Breakthrough Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Breakthrough Therapies Revenue Share by Type (2021-2032) Figure 48. China Breakthrough Therapies Revenue Share by Application (2021-2032) Figure 49. Asia Breakthrough Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Breakthrough Therapies Revenue Share by Type (2021-2032) Figure 51. Asia Breakthrough Therapies Revenue Share by Application (2021-2032) Figure 52. Asia Breakthrough Therapies Revenue Share by Region (2021-2032) Figure 53. Japan Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Breakthrough Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Breakthrough Therapies Revenue Share by Type (2021-2032) Figure 61. SAMEA Breakthrough Therapies Revenue Share by Application (2021-2032) Figure 62. SAMEA Breakthrough Therapies Revenue Share by Country (2021-2032) Figure 63. Brazil Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Breakthrough Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Immunotherapy
  • Gene Therapy
  • Cell Therapy
  • Other
Applications
  • Cardiovascular
  • Central Nervous System and Neurology
  • Rare Diseases
  • Oncology
  • Others
Companies covered
  • F. Hoffmann-La Roche
  • Merck & Co.
  • Bristol-Myers Squibb
  • Novartis
  • AstraZeneca
  • Johnson & Johnson
  • Pfizer
  • AbbVie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Breakthrough Therapies Market by Type
  3. 1.2.1 Global Breakthrough Therapies Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Targeted Therapy
  5. 1.2.3 Immunotherapy
  6. 1.2.4 Gene Therapy
  7. 1.2.5 Cell Therapy
  8. 1.2.6 Other
  9. 1.3 Breakthrough Therapies Market by Application
  10. 1.3.1 Global Breakthrough Therapies Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Cardiovascular
  12. 1.3.3 Central Nervous System and Neurology
  13. 1.3.4 Rare Diseases
  14. 1.3.5 Oncology
  15. 1.3.6 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Breakthrough Therapies Market Dynamics
  1. 2.1 Breakthrough Therapies Industry Trends
  2. 2.2 Breakthrough Therapies Industry Drivers
  3. 2.3 Breakthrough Therapies Industry Opportunities and Challenges
  4. 2.4 Breakthrough Therapies Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Breakthrough Therapies Market Perspective (2021-2032)
  2. 3.2 Global Breakthrough Therapies Growth Trends by Region
  3. 3.2.1 Global Breakthrough Therapies Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Breakthrough Therapies Market Size by Region (2021-2026)
  5. 3.2.3 Global Breakthrough Therapies Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Breakthrough Therapies Revenue by Players
  2. 4.1.1 Global Breakthrough Therapies Revenue by Players (2021-2026)
  3. 4.1.2 Global Breakthrough Therapies Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Breakthrough Therapies Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Breakthrough Therapies Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Breakthrough Therapies Key Players Headquarters & Area Served
  7. 4.4 Global Breakthrough Therapies Players, Product Type & Application
  8. 4.5 Global Breakthrough Therapies Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Breakthrough Therapies Market CR5 and HHI
  11. 4.6.3 2025 Breakthrough Therapies Tier 1, Tier 2, and Tier 3
5 Breakthrough Therapies Market Size by Type
  1. 5.1 Global Breakthrough Therapies Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Breakthrough Therapies Revenue by Type (2021-2032)
  3. 5.3 Global Breakthrough Therapies Revenue Market Share by Type (2021-2032)
6 Breakthrough Therapies Market Size by Application
  1. 6.1 Global Breakthrough Therapies Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Breakthrough Therapies Revenue by Application (2021-2032)
  3. 6.3 Global Breakthrough Therapies Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 F. Hoffmann-La Roche
  2. 7.1.1 F. Hoffmann-La Roche Company Information
  3. 7.1.2 F. Hoffmann-La Roche Business Overview
  4. 7.1.3 F. Hoffmann-La Roche Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  5. 7.1.4 F. Hoffmann-La Roche Breakthrough Therapies Product Portfolio
  6. 7.1.5 F. Hoffmann-La Roche Recent Developments
  7. 7.2 Merck & Co.
  8. 7.2.1 Merck & Co. Company Information
  9. 7.2.2 Merck & Co. Business Overview
  10. 7.2.3 Merck & Co. Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck & Co. Breakthrough Therapies Product Portfolio
  12. 7.2.5 Merck & Co. Recent Developments
  13. 7.3 Bristol-Myers Squibb
  14. 7.3.1 Bristol-Myers Squibb Company Information
  15. 7.3.2 Bristol-Myers Squibb Business Overview
  16. 7.3.3 Bristol-Myers Squibb Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bristol-Myers Squibb Breakthrough Therapies Product Portfolio
  18. 7.3.5 Bristol-Myers Squibb Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Breakthrough Therapies Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Breakthrough Therapies Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 Johnson & Johnson
  32. 7.6.1 Johnson & Johnson Company Information
  33. 7.6.2 Johnson & Johnson Business Overview
  34. 7.6.3 Johnson & Johnson Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Johnson & Johnson Breakthrough Therapies Product Portfolio
  36. 7.6.5 Johnson & Johnson Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Breakthrough Therapies Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 AbbVie
  44. 7.8.1 AbbVie Company Information
  45. 7.8.2 AbbVie Business Overview
  46. 7.8.3 AbbVie Breakthrough Therapies Revenue and Gross Margin (2021-2026)
  47. 7.8.4 AbbVie Breakthrough Therapies Product Portfolio
  48. 7.8.5 AbbVie Recent Developments
8 North America
  1. 8.1 North America Breakthrough Therapies Revenue (2021-2032)
  2. 8.2 North America Breakthrough Therapies Revenue by Type (2021-2032)
  3. 8.2.1 North America Breakthrough Therapies Revenue by Type (2021-2026)
  4. 8.2.2 North America Breakthrough Therapies Revenue by Type (2027-2032)
  5. 8.3 North America Breakthrough Therapies Revenue Share by Type (2021-2032)
  6. 8.4 North America Breakthrough Therapies Revenue by Application (2021-2032)
  7. 8.4.1 North America Breakthrough Therapies Revenue by Application (2021-2026)
  8. 8.4.2 North America Breakthrough Therapies Revenue by Application (2027-2032)
  9. 8.5 North America Breakthrough Therapies Revenue Share by Application (2021-2032)
  10. 8.6 North America Breakthrough Therapies Revenue by Country
  11. 8.6.1 North America Breakthrough Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Breakthrough Therapies Revenue by Country (2021-2026)
  13. 8.6.3 North America Breakthrough Therapies Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Breakthrough Therapies Revenue (2021-2032)
  2. 9.2 Europe Breakthrough Therapies Revenue by Type (2021-2032)
  3. 9.2.1 Europe Breakthrough Therapies Revenue by Type (2021-2026)
  4. 9.2.2 Europe Breakthrough Therapies Revenue by Type (2027-2032)
  5. 9.3 Europe Breakthrough Therapies Revenue Share by Type (2021-2032)
  6. 9.4 Europe Breakthrough Therapies Revenue by Application (2021-2032)
  7. 9.4.1 Europe Breakthrough Therapies Revenue by Application (2021-2026)
  8. 9.4.2 Europe Breakthrough Therapies Revenue by Application (2027-2032)
  9. 9.5 Europe Breakthrough Therapies Revenue Share by Application (2021-2032)
  10. 9.6 Europe Breakthrough Therapies Revenue by Country
  11. 9.6.1 Europe Breakthrough Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Breakthrough Therapies Revenue by Country (2021-2026)
  13. 9.6.3 Europe Breakthrough Therapies Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Breakthrough Therapies Revenue (2021-2032)
  2. 10.2 China Breakthrough Therapies Revenue by Type (2021-2032)
  3. 10.2.1 China Breakthrough Therapies Revenue by Type (2021-2026)
  4. 10.2.2 China Breakthrough Therapies Revenue by Type (2027-2032)
  5. 10.3 China Breakthrough Therapies Revenue Share by Type (2021-2032)
  6. 10.4 China Breakthrough Therapies Revenue by Application (2021-2032)
  7. 10.4.1 China Breakthrough Therapies Revenue by Application (2021-2026)
  8. 10.4.2 China Breakthrough Therapies Revenue by Application (2027-2032)
  9. 10.5 China Breakthrough Therapies Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Breakthrough Therapies Revenue (2021-2032)
  2. 11.2 Asia Breakthrough Therapies Revenue by Type (2021-2032)
  3. 11.2.1 Asia Breakthrough Therapies Revenue by Type (2021-2026)
  4. 11.2.2 Asia Breakthrough Therapies Revenue by Type (2027-2032)
  5. 11.3 Asia Breakthrough Therapies Revenue Share by Type (2021-2032)
  6. 11.4 Asia Breakthrough Therapies Revenue by Application (2021-2032)
  7. 11.4.1 Asia Breakthrough Therapies Revenue by Application (2021-2026)
  8. 11.4.2 Asia Breakthrough Therapies Revenue by Application (2027-2032)
  9. 11.5 Asia Breakthrough Therapies Revenue Share by Application (2021-2032)
  10. 11.6 Asia Breakthrough Therapies Revenue by Country
  11. 11.6.1 Asia Breakthrough Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Breakthrough Therapies Revenue by Country (2021-2026)
  13. 11.6.3 Asia Breakthrough Therapies Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Breakthrough Therapies Revenue (2021-2032)
  2. 12.2 SAMEA Breakthrough Therapies Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Breakthrough Therapies Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Breakthrough Therapies Revenue by Type (2027-2032)
  5. 12.3 SAMEA Breakthrough Therapies Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Breakthrough Therapies Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Breakthrough Therapies Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Breakthrough Therapies Revenue by Application (2027-2032)
  9. 12.5 SAMEA Breakthrough Therapies Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Breakthrough Therapies Revenue by Country
  11. 12.6.1 SAMEA Breakthrough Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Breakthrough Therapies Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Breakthrough Therapies Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst